Coherus Oncology (NASDAQ: CHRS) net income
Coherus Oncology reported a net profit of $168.0m for fiscal 2025, 489.4% more than in fiscal 2024 ($28.5m). Its net margin was 398.4%. Earnings per share were $1.43.
Fiscal 2025 is the highest of the 10 fiscal years on record for Coherus Oncology. It reported a loss in 6 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $168.0m | +489.4% | 398.4% | $1.43 |
| 2024 | $28.5m | — | 108.0% | $0.25 |
| 2023 | −$237.9m | — | −92.5% | −$2.53 |
| 2022 | −$291.8m | — | −138.2% | −$3.76 |
| 2021 | −$287.1m | −317.1% | −87.9% | −$3.81 |
| 2020 | $132.2m | +47.2% | 27.8% | $1.85 |
| 2019 | $89.8m | — | 25.2% | $1.29 |
| 2018 | −$209.3m | — | — | −$3.22 |
| 2017 | −$238.2m | — | −15,306.6% | −$4.48 |
| 2016 | −$127.3m | — | −67.0% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Coherus Oncology net income compared with its sector
By net income for its latest fiscal year, Coherus Oncology ranks 97th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Coherus Oncology, 398.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 95th | Bio-Techne | $181.9m | 15.0% |
| 96th | Penumbra | $177.7m | 12.7% |
| 97th | Coherus Oncology | $168.0m | 398.4% |
| 98th | Concentra Group Holdings Parent | $166.4m | 7.7% |
| 99th | Pediatrix Medical Group | $165.4m | 8.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Coherus Oncology
- How much did Coherus Oncology earn in fiscal 2025?
- Coherus Oncology reported a net profit of $168.0m for fiscal 2025. In fiscal 2024 it reported a net profit of $28.5m.
- What are the earnings per share of Coherus Oncology?
- They were $1.43 in fiscal 2025, compared with $0.25 in fiscal 2024.
- What is the net margin of Coherus Oncology?
- In fiscal 2025 its net profit was 398.4% of its revenue.
- What was the most profitable year for Coherus Oncology?
- Of its last 10 fiscal years, fiscal 2025, with $168.0m.
- Where does Coherus Oncology rank in its sector by net income?
- It ranks 97th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Coherus Oncology come from?
- From the annual report (Form 10-K) that Coherus Oncology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Coherus Oncology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Coherus Oncology: the Coherus Oncology page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.